This fund gives investors exposure to the small cap health care industry, a market segment that has both value and growth characteristics. Securities in this corner of the market can be also be prone to quick shifts in sentiment thanks to changing government regulations or policies. Furthermore, many companies in this corner of the market are unprofitable and rely on FDA drug approval in order to snap back into the green, a very risky proposition. With that being said, PSCH gives investors a nice mix of biotech, pharma, medical tech, and facility companies spreading risk around the various corners of the health care world. However, it should be noted that the fund does still have singificant concentrattion in its top ten holdings as these companies make up close to one third of total assets, rather high considering the fund only has 70 securities in total. As a result, investors should consider this fund only if they are looking to tactically tilt towards the sector or round out exposure to the health care segment.